Given that research indicates a potential link between HER2-positive DCIS and elevated breast cancer recurrence rates, along with adverse clinicopathological characteristics [43], further investigation into the significance of HER2-low expression in both DCIS and LCIS is warranted for future studies. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.